翻訳と辞書 |
Briakinumab
Briakinumab (ABT-874) is a human monoclonal antibody being developed by Abbott Laboratories for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. Like ustekinumab, the antibody targets the interleukins 12 and 23. ==Discovery== The candidate drug was discovered by Cambridge Antibody Technology in collaboration with Abbott.〔(MedImmune: External R&D Partnering )〕
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Briakinumab」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|